[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"feasibility-pilot-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:feasibility-pilot-study":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,76,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100634600","relaxing-virtual-reality-use-and-blood-glucose-response-to-food-revir-study-100634600",false,"NCT07541794","Relaxing Virtual Reality Use and Blood Glucose Response to Food (ReViR) Study","Participants must meet all of the following criteria to be eligible for the study:\n\n1. Aged between 18 and 50 years, of any sex.\n2. Body mass index (BMI) between 18.9 and 29.9 kg\u002Fm².\n3. Fasting blood glucose between 3.5 and 5.6 mmol\u002FL.\n4. They typically consume breakfast as part of their regular routine.\n5. Willing and able to provide written informed consent.\n6. In the opinion of the Investigator, the participant is capable of understanding and adhering to all study requirements.\n\nParticipants will be excluded if they meet any of the following conditions:\n\n1. Fasting blood glucose ≥ 5.6 mmol\u002FL or \\\u003C 3.5 mmol\u002FL.\n2. Medical conditions that contraindicate the use of virtual reality (VR) headsets, including panic disorders, seizure disorders, migraines, certain vision impairments, or VR-related motion sickness.\n3. A history of allergy or adverse reaction to white bread.\n4. Current adherence to a special diet or use of supplements\u002Fmedications that may affect carbohydrate metabolism, heart rate, or the nervous system within the last 6 months.\n5. Medical history of hypertension, HIV\u002FAIDS, hepatitis, type 1 or type 2 diabetes, cardiovascular or pulmonary diseases, or gastrointestinal disorders impacting carbohydrate metabolism.\n6. Major physical injury or surgical procedure within the last 3 months.\n7. Participation in any other randomized controlled trial within the previous 3 months.\n8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period.\n9. Being unable to consume the test meal within the required 10-minute timeframe.\n10. History of cancer within the past two years, excluding non-melanoma skin cancers.\n11. Current or recent (within 12 months) excessive alcohol use defined as more than 14 standard drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits).\n12. Significant weight change (gain or loss exceeding 3.5 kg) in the past 3 months.\n13. Inability to provide written informed consent.",true,"ALL","18 Years","50 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized cross-over pilot clinical trial aims to evaluate the feasibility and effect of a relaxing virtual reality (VR) experience on glucose response after white bread consumption, compared to a stress-inducing VR, a VR clinical room, and a real clinical room, in healthy adults. Participants will use a head-mounted display to experience either one of the VR environments, or they will simply sit in an actual clinical room for 15 minutes. After this pre-meal condition, participants will consume 66 grams of white bread within 10 minutes, accompanied by 250 mL of water. They will then continue their assigned pre-meal condition for one hour, followed by an additional hour of sitting in the lab for further assessments.\n\nThe feasibility of the study will be assessed by calculating: 1) Screening to randomization ratio, 2) Recruitment rate of participants per week, 3) Retention rate, 4) Data Completeness of Finger-Prick Glucose Measurements, and 5) VR intervention tolerability measured by Simulator Sickness Questionnaire (SSQ) score. Postprandial glucose response, stress levels, heart rate, and skin conductance will be assessed at baseline (15 minutes before white bread consumption), immediately before consumption (time 0), and at 15, 30, 45, 60, 90, and 120 minutes post-consumption. Palatability will be evaluated immediately after the meal consumption. Motivation to eat will also be assessed at 0, 15, 30, 45, 60, 90, and 120 minutes. Sense of presence will be measured immediately after VR exposure. Additionally, simulator sickness will be assessed at the beginning of the study and after VR exposure.\n\nThe results will help us better understand the potential feasibility and benefits of using relaxing VR for postprandial glucose management. These findings will also provide evidence to optimize the design of future definitive randomized clinical trials and enhance the development of VR interventions.",[27,28],"Post Prandial Blood Glucose","Feasibility Pilot Study","NOT_YET_RECRUITING","2026-04-16",{"date":32,"type":33},"2026-04-21","ACTUAL",{"date":35,"type":21},"2026-05-01",{"date":37,"type":21},"2027-02-01",{"name":39,"class":40},"University of Manitoba","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100601102","phase-4-antibiotics-for-kidney-transplant-recipients-100601102","NCT07106125","Antibiotics for Kidney Transplant Recipients","Trial of Antibiotic Strategies for Kidney Transplant Recipients","TASK","Inclusion Criteria:\n\n* Must be able to take capsules orally\n* Kidney transplant performed at a UCSF facility within the last 6 months\n* Most recent glomerular filtration rate (GFR) \\>30 mL\u002Fmin\u002F1.73 m2\n* Tolerated initial 6 months of post-transplant TMP-SMX (defined as no intentional periods of TMP-SMX cessation in first 6 months after transplant due to hyperkalemia, allergic reaction, or unexpected\u002Fexcessive neutropenia)\n* Considered \"high risk for UTI\" after kidney transplant, as defined by one or more of the following: (1) Congenital anomaly of kidney\u002Furinary tract as kidney failure etiology, (2) Diagnosis of neurogenic bladder and\u002For use of clean intermittent catheterization and\u002For nightly continuous urinary drainage, (3) Diabetes mellitus (diagnosed either prior to or new-onset after transplant), (4) History of recurrent UTIs as diagnosed by a provider prior to transplant, (5) Occurrence of any UTI in first 6 months after transplant, (6) Delayed graft function (defined as need for dialysis within 7 days of transplant)\n\nExclusion Criteria:\n\n* History of intolerance or allergy to trimethoprim (TMP) and\u002For sulfamethoxazole (SMX)\n* History of UTI due to a TMP-SMX-resistant organism in the first 6 months after transplant\n* Moderate or severe neutropenia (absolute neutrophil count \\\u003C1,000 cells\u002FμL) on most recent bloodwork available at the time of recruitment\n* Uncontrolled hyperkalemia (serum potassium ≥5.0 mEq\u002FL) on most recent bloodwork available at the time of recruitment\n* Provider-determined\u002Fdocumented need for either continuation or discontinuation of TMP-SMX prophylaxis that would preclude the patient's randomization\n* Current pregnancy\n* Incarcerated individuals\u002Fprisoners\n* Inability to provide informed consent or assent, and no legally authorized representative available","29 Years",{"count":51,"type":21},50,[53],"PHASE4","The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.\n\nThe main questions this study is asking are:\n\n* Does TMP-SMX lower the number of UTIs in the first year after transplant?\n* What side effects or problems do participants have while taking TMP-SMX?\n\nResearchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.\n\nParticipants will:\n\n* Take either TMP-SMX or a placebo pill by mouth every day for 6 months\n* Have three visits to touch base with the study team about any issues\n* Complete short monthly online surveys about any symptoms or side effects\n* Share blood and urine test results from their regular transplant clinic visits",[56,57,58,59,28],"Kidney Transplant","Urinary Tract Infection(UTI)","Antibiotic Prophylaxis","Remote Patient Monitoring",[61,62,63,64,65],"kidney transplant","UTI prevention","antibiotic prophylaxis","decentralized trial","remote clinical trial","2025-10-29",{"date":68,"type":33},"2025-10-31",{"date":70,"type":21},"2026-11",{"date":72,"type":21},"2029-01",{"name":74,"class":40},"University of California, San Francisco",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":5},"100584005","feasibility--preliminary-impacts-of-an-online-psychoeducational-program-isupport-malaysia-for-informal-dementia-caregivers-100584005","NCT06883708","Feasibility & Preliminary Impacts of an Online Psychoeducational Program (iSupport-Malaysia) for Informal Dementia Caregivers","iSupport-Malaysia: An Online Psychoeducational Intervention Program for Informal Dementia Caregivers in Malaysia - A Pilot Feasibility Study","Inclusion Criteria:\n\n* Aged 18 years and older, any gender\n* Able to understand written Malay language\n* A self-reported caregiver of person living with any form of dementia (defined by a score of ≥ 2 on the AD8)\n* Provide unpaid care to the PLWD for at least 6 months at the time of recruitment\n* Experience some extent of psychological distress, such that they should experience some levels of subjective burden (defined by a score of ≥ 4 on the 1-item burden scale ranging from 1 to 10), OR some symptoms of depression OR anxiety (defined by a score of ≥ 8 on either the 'depression' or 'anxiety' subscales of HADS)\n* Regular internet user, defined as using the internet at least twice a week.\n\nExclusion Criteria:\n\n* Already participated in Phase 1 iSupport-Malaysia studies (focus groups, usability testing)\n* Where another family member in the same household has participated\u002F currently participating in the iSupport study\n* Have limited comprehension of written Malay language\n* Do not have access to a device with an internet connection (e.g. mobile phone, tablet, laptop, desktop) more than twice a week\n* Unable or unwilling to provide written informed consent","100 Years",{"count":85,"type":21},70,[24],"The general objective of this pilot feasibility study is to implement the pilot randomised controlled trial (RCT) and evaluate the feasibility of its methods and procedures for iSupport-Malaysia intervention. Another objective is to assess the acceptability and preliminary impacts of the iSupport-Malaysia web-based intervention on the psychological well-being of informal caregivers (ICs) of persons living with dementia (PLWDs) in Malaysia, compared to iSupport-Malaysia eBook.\n\nThe main questions this pilot study aims to answer are:\n\n1. How feasible is it to implement iSupport-Malaysia as an accessible resource for ICs of PLWD in Malaysia?\n2. Does the use of iSupport-Malaysia lead to a reduction in caregiver burden among the ICs of PLWD in both web and eBook conditions?\n3. Does the use of iSupport-Malaysia lead to improvements in psychological well-being (e.g. reduced depression, anxiety, stress; and increased quality of life) among the ICs of PLWD in both web and eBook conditions?\n4. What are the perceptions of ICs of PLWD on the usability, satisfaction and perceived usefulness of the modules in iSupport-Malaysia?\n\nTo answer these research questions:\n\nSeventy ICs of PLWD who met the study criteria will be recruited from the geriatric facilities of three hospitals, as well as via social media and referrals from elderly care centres.\n\nEligible participants will sign an informed consent form, and be randomly assigned to the intervention (iSupport-Malaysia web program) or active comparison group (iSupport-Malaysia eBook) using stratified block randomisation.\n\nIn both arms, participants are required to complete at least 10 out of 23 lessons within 3 months.\n\nOutcome measures will be administered online at baseline, 1-month and 3-month follow-up.\n\nFeasibility outcomes will also be measured. Upon completion of the program, ICs in the experimental group will be invited for in-depth interviews via an online teleconferencing platform.\n\nExpected outputs:\n\nA free, adaptive web-based iSupport-Malaysia in the local Malay language. iSupport-Malaysia can facilitate self-directed training in public and private dementia services, integrate into caregiver training programs, and promote self-directed public education on dementia care.",[89,90,28],"Caregiver Subjective Burden","Caregiver Wellbeing",[92,93,94,95,96],"informal caregivers","dementia","caregiver support","internet-based intervention","psychoeducation","RECRUITING","2025-03-13",{"date":100,"type":33},"2025-03-19",{"date":102,"type":33},"2025-02-05",{"date":104,"type":21},"2026-12",{"name":106,"class":40},"Sunway University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":75},"100582044","phase-2-promoting-active-therapy-path-to-wellness-100582044","NCT06858189","Promoting Active Therapy: Path to Wellness","Can Nature-based Physical Activity Improve Symptoms of Depression and Anxiety?","Inclusion Criteria:\n\n* Current client of a participating therapist who has completed study training\n* Diagnosed depressive or anxiety disorder\n* Able to safely engage in moderate physical activity\n* Willing to complete all study requirements\n\nExclusion Criteria:\n\n* Planning to discontinue therapy in less than 6 months\n* Active suicidal ideation\n* Does not pass exercise risk screener","65 Years",{"count":116,"type":21},60,[118],"PHASE2","This project will examine changes in depression and anxiety following a 10-week intervention promoting nature-based physical activity in mental health settings. We will recruit ten licensed therapists whose caseload includes adults with depression and anxiety. Following a training by our team, each participating therapist will recruit six clients, who will be randomly assigned to the intervention or control condition. Clients in the intervention condition will engage in walk-and-talk therapy outdoors during weekly sessions and discuss strategies for being active outdoors on their own. We will assess changes in depression, anxiety, and nature-based physical activity in both groups.",[121,122,123,124,28],"Depression, Anxiety","Physical Activity","Time in Nature","Self-Efficacy",[126,127,128,129,130,131],"therapy","nature prescriptions","park prescriptions (ParkRx)","exercise","mental health","walk-and-talk","2025-02-27",{"date":134,"type":33},"2025-03-05",{"date":136,"type":33},"2025-02-28",{"date":138,"type":21},"2026-05-31",{"name":140,"class":40},"Kansas State University"]